RBBP8 Antibody
Code | Size | Price |
---|
PSI-5761-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-5761-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
RBBP8 Antibody: RIM, COM1, CTIP, JWDS, SAE2, SCKL2, DNA endonuclease RBBP8, CtBP-interacting protein, CtIP
Application Note:
RBBP8 antibody can be used for detection of RBBP8 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.
Background:
RBBP8 Antibody: RBBP8, also known as CtBP (carboxy-terminal binding protein) interacting protein (CTIP), was characterized for its role in transcription as a cofactor for the transcriptional repressor CtBP, and also as a binding partner for other proteins including the cell cycle regulators retinoblastoma protein (Rb) and breast cancer 1 (BRCA1). It is ubiquitously expressed and localizes to the nucleus. RBBP8 is thought to modulate the functions in cell proliferation, transcriptional regulation and DNA repair. RBBP8 also plays a central role in the cell cycle checkpoint response to DNA double-stranded breaks (DSBs), with new evidence demonstrating that it controls the choice of DSB repair pathway.
Background References:
- Yu X, Wu LC, Bowcock AM, et al. The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J. Biol. Chem.1998; 273:25388-92.
- Liu F and Lee WH. CtIP activates its own and cyclin D1 promoters via the E2F/RB pathway during G1/S progression. Mol. Cell Biol.2006; 26:3124-34.
- Sterner JM, Dew-Knight S, Musahl C, et al. Negative regulation of DNA replication by the retinoblastoma protein is mediated by its association with MCM7. Mol. Cell Biol.1998; 18:2748-57.
- Wu G and Lee WH. CtIP, a multivalent adaptor connecting transcriptional regulation, checkpoint control and tumor suppression. Cell Cycle2006; 5:1592-6.
Buffer:
RBBP8 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
RBBP8 antibody was raised against a 14 amino acid synthetic peptide near the center of human RBBP8.
The immunogen is located within amino acids 430 - 480 of RBBP8.
The immunogen is located within amino acids 430 - 480 of RBBP8.
NCBI Gene ID #:
5932
NCBI Official Name:
retinoblastoma binding protein 8
NCBI Official Symbol:
RBBP8
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_976037
Protein GI Number:
42718017
Purification:
RBBP8 Antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer,Cell Cycle
Swissprot #:
Q99708
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
Product Name | Product Code | Supplier | RBBP8 Peptide | PSI-5761P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|